Bal Pharma Limited (BALPHARMA) - Total Assets
Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) holds total assets worth Rs3.49 Billion INR (≈ $37.78 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Bal Pharma Limited for net asset value and shareholders' equity analysis.
Bal Pharma Limited - Total Assets Trend (2006–2025)
This chart illustrates how Bal Pharma Limited's total assets have evolved over time, based on quarterly financial data.
Bal Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Bal Pharma Limited's total assets of Rs3.49 Billion consist of 70.0% current assets and 30.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs80.50 Million | 2.4% |
| Accounts Receivable | Rs935.76 Million | 27.9% |
| Inventory | Rs1.03 Billion | 30.7% |
| Property, Plant & Equipment | Rs737.76 Million | 22.0% |
| Intangible Assets | Rs119.97 Million | 3.6% |
| Goodwill | Rs38.27 Million | 1.1% |
Asset Composition Trend (2006–2025)
This chart illustrates how Bal Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BALPHARMA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bal Pharma Limited's current assets represent 70.0% of total assets in 2025, an increase from 66.9% in 2006.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2025, down from 6.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 30.7% of total assets.
Bal Pharma Limited Competitors by Total Assets
Key competitors of Bal Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Bal Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.07 | 1.12 | 1.03 |
| Quick Ratio | 0.58 | 0.72 | 0.70 |
| Cash Ratio | 0.04 | 0.06 | 0.00 |
| Working Capital | Rs161.13 Million | Rs274.98 Million | Rs50.17 Million |
Bal Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Bal Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.42 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | Rs3.36 Billion |
| Market Capitalization | $13.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bal Pharma Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bal Pharma Limited's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bal Pharma Limited (2006–2025)
The table below shows the annual total assets of Bal Pharma Limited from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs3.36 Billion ≈ $36.30 Million |
+5.06% |
| 2024-03-31 | Rs3.20 Billion ≈ $34.56 Million |
+2.03% |
| 2023-03-31 | Rs3.13 Billion ≈ $33.87 Million |
+20.20% |
| 2022-03-31 | Rs2.61 Billion ≈ $28.18 Million |
+8.52% |
| 2021-03-31 | Rs2.40 Billion ≈ $25.96 Million |
+0.71% |
| 2020-03-31 | Rs2.38 Billion ≈ $25.78 Million |
-8.77% |
| 2019-03-31 | Rs2.61 Billion ≈ $28.26 Million |
+3.77% |
| 2018-03-31 | Rs2.52 Billion ≈ $27.23 Million |
+9.38% |
| 2017-03-31 | Rs2.30 Billion ≈ $24.90 Million |
+9.09% |
| 2016-03-31 | Rs2.11 Billion ≈ $22.82 Million |
+28.78% |
| 2015-03-31 | Rs1.64 Billion ≈ $17.72 Million |
+5.89% |
| 2014-03-31 | Rs1.55 Billion ≈ $16.73 Million |
+3.27% |
| 2013-03-31 | Rs1.50 Billion ≈ $16.20 Million |
+6.14% |
| 2012-03-31 | Rs1.41 Billion ≈ $15.27 Million |
+4.33% |
| 2011-03-31 | Rs1.35 Billion ≈ $14.63 Million |
+8.94% |
| 2010-03-31 | Rs1.24 Billion ≈ $13.43 Million |
+2.19% |
| 2009-03-31 | Rs1.22 Billion ≈ $13.14 Million |
+11.66% |
| 2008-03-31 | Rs1.09 Billion ≈ $11.77 Million |
+20.23% |
| 2007-03-31 | Rs905.28 Million ≈ $9.79 Million |
+2.75% |
| 2006-03-31 | Rs881.03 Million ≈ $9.53 Million |
-- |
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more